A pharmaceutical composition of venetoclax and a preparation method thereof

By using a preparation method that does not involve liquid surfactants, a Venecra drug composition is prepared using solid powder materials, which solves the problems of material accumulation and poor stability in the prior art and achieves high stability and suitability for industrial production.

CN123059059APending Publication Date: 2026-11-10SHANGHAI HANHERUI PHARM TECH CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202611593450.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-15
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing veneclade formulations suffer from problems such as material accumulation, high equipment costs, uneven dispersion, and poor stability during preparation, making them unsuitable for industrial production.

Method used

A preparation method without liquid surfactants is adopted, using solid powder materials containing Venecra, water-soluble polymer carrier, filler, flow aid and lubricant, to prepare Venecra solid dispersions by hot melt extrusion and pulverization, which simplifies the process and improves stability.

Benefits of technology

It reduces processing difficulty, improves formulation stability and dissolution performance, significantly reduces the content of related substances, is suitable for industrial production, and the dissolution curve fits the reference formulation, with stability meeting quality standards.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123059059A_ABST
    Figure CN123059059A_ABST
Patent Text Reader

Abstract

This invention provides a veneclade pharmaceutical composition and its preparation method. The pharmaceutical composition of this invention comprises a solid dispersion and excipients; the solid dispersion comprises veneclade and a water-soluble polymer carrier, and the excipients comprise fillers, flow aids, and lubricants, optionally including solubilizers. The pharmaceutical composition of this invention has significantly lower levels of related substances than a reference formulation, its dissolution profile can be matched with the reference formulation, and its stability meets quality standards; furthermore, the excipients do not contain liquid surfactants, the preparation process is simple, the processing difficulty is low, and it is suitable for commercial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical formulation technology, specifically to a Veneclare pharmaceutical composition and its preparation method. Background Technology

[0002] Acute myeloid leukemia (AML) is an aggressive malignant hematologic disorder characterized by abnormal growth and differentiation of hematopoietic stem cells (HSCs). The World Health Organization (WHO) defines it as a bone marrow tumor containing ≥20% blast cells in the peripheral blood or bone marrow. Clinically, it is mainly characterized by anemia, bleeding, fever, and leukemic cell infiltration. Studies have shown that overexpression of the B-cell lymphoma-2 gene (Bcl-2) is involved in the maintenance and survival of AML cells and is associated with tumor resistance to chemotherapy drugs. Furthermore, high levels of Bcl-2 are associated with poorer survival rates in this subgroup of patients. Venetoclax, developed by AbbVie, is a highly effective, selective, orally bioavailable small molecule inhibitor of Bcl-2, and its tablets were approved by the FDA for marketing in the United States on April 11, 2016. Veneclare's chemical name is 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide), and its structural formula is shown below: Venecra tablets (brand name: Venclavula®) ® The original formulation used the following excipients: copovidone, colloidal silica, polysorbate 80, sodium stearate fumarate, and anhydrous calcium hydrogen phosphate. According to the BCS classification, veneclade belongs to BCS class IV compounds, characterized by low solubility, poor permeability, and poor bioavailability in vivo. The original formulation process used hot-melt extrusion technology to prepare a solid dispersion of veneclade, thereby increasing its solubility, improving its absorption in vivo, and ultimately enhancing its bioavailability.

[0003] Patent CN103282025B discloses a method for preparing a solid dispersion of vinecrate. The inventors, in repeating the process of CN103282025B, discovered that granulating copovidone, polysorbate 80, and colloidal silica, followed by mixing and sieving with vinecrate raw material, resulted in loose, easily agglomerated granules. During extrusion, the material accumulated at the extruder inlet, hindering smooth extrusion, and the resulting solid dispersion had a high level of related substances. Furthermore, the process described in CN103282025B uses a liquid metering system to add polysorbate 80 to the solid dispersion during extrusion, placing high demands on the metering system, increasing equipment costs, and being susceptible to uneven liquid addition due to the fluid state of polysorbate 80. This ultimately leads to uneven dispersion of polysorbate 80 in the solid dispersion, affecting the content, related substances, and dissolution rate of the final product.

[0004] Therefore, there is an urgent need in this field to develop a novel Veneclare drug composition that is simple to prepare, has good stability, and is suitable for industrial production. Summary of the Invention

[0005] To address the aforementioned technical problems, this invention provides a Veneclare pharmaceutical composition without liquid surfactants and its preparation method. The materials used in the preparation process are all solid powders, which greatly reduces the processing difficulty and simplifies the preparation process. At the same time, the composition has low content of related substances, good stability, and is suitable for industrial production.

[0006] In a first aspect of the invention, a veneclade pharmaceutical composition is provided, the pharmaceutical composition comprising veneclade, a water-soluble polymer carrier, a filler, a flow aid, and a lubricant, optionally comprising a solubilizer.

[0007] In a preferred embodiment, the water-soluble polymer carrier is selected from the group consisting of: copovidone, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus), polyvinyl alcohol, or hydroxypropyl methylcellulose.

[0008] In a preferred embodiment, the water-soluble polymer carrier is selected from the group consisting of copovidone or Soluplus.

[0009] In a preferred embodiment, the filler is selected from the group consisting of anhydrous dicalcium phosphate, microcrystalline cellulose, lactose, or starch.

[0010] In a preferred embodiment, the filler is anhydrous dicalcium phosphate.

[0011] In a preferred embodiment, the solubilizer is selected from the group consisting of: poloxamer, sodium lauryl sulfate, Soluplus, or vitamin E polyethylene glycol succinate.

[0012] In a preferred embodiment, the solubilizer is selected from the group consisting of poloxamer, sodium dodecyl sulfate, or Soluplus.

[0013] In a preferred embodiment, the solubilizer is poloxamer.

[0014] In a preferred embodiment, the flow aid is selected from the group consisting of colloidal silica or talc.

[0015] In a preferred embodiment, the flow aid is colloidal silica.

[0016] In a preferred embodiment, the lubricant is selected from the group consisting of sodium stearate fumarate or magnesium stearate.

[0017] In a preferred embodiment, the lubricant is sodium stearate fumarate.

[0018] In a preferred embodiment, the present invention provides a veneclade pharmaceutical composition comprising veneclade, a water-soluble polymer carrier, a filler, a flow aid, a lubricant, and a solubilizer, wherein the water-soluble polymer carrier is copovidone, the filler is anhydrous calcium hydrogen phosphate, the flow aid is colloidal silica, the lubricant is sodium stearate fumarate, and the solubilizer is poloxamer.

[0019] In a preferred embodiment, the present invention provides a veneclade pharmaceutical composition comprising veneclade, a water-soluble polymer carrier, a filler, a flow aid, a lubricant, and a solubilizer, wherein the water-soluble polymer carrier is copovidone, the filler is anhydrous calcium hydrogen phosphate, the flow aid is colloidal silica, the lubricant is sodium stearate fumarate, and the solubilizer is sodium dodecyl sulfate.

[0020] In a preferred embodiment, the present invention provides a veneclade pharmaceutical composition comprising veneclade, a water-soluble polymer carrier, a filler, a flow aid, a lubricant, and a solubilizer, wherein the water-soluble polymer carrier is copovidone, the filler is anhydrous calcium hydrogen phosphate, the flow aid is colloidal silica, the lubricant is sodium stearate fumarate, and the solubilizer is Soluplus.

[0021] In a preferred embodiment, the present invention provides a veneclade pharmaceutical composition comprising veneclade, a water-soluble polymer carrier, a filler, a flow aid, a lubricant, and a solubilizer, wherein the water-soluble polymer carrier is Soluplus, the filler is anhydrous calcium hydrogen phosphate, the flow aid is colloidal silica, the lubricant is sodium stearate fumarate, and the solubilizer is poloxamer.

[0022] In a preferred embodiment, the present invention provides a veneclade pharmaceutical composition comprising veneclade, a water-soluble polymer carrier, a filler, a flow aid, a lubricant, and a solubilizer, wherein the water-soluble polymer carrier is Soluplus, the filler is anhydrous calcium hydrogen phosphate, the flow aid is colloidal silica, the lubricant is sodium stearate fumarate, and the solubilizer is sodium dodecyl sulfate.

[0023] In a preferred embodiment, the present invention provides a Venecra pharmaceutical composition comprising Venecra, a water-soluble polymer carrier, a filler, a flow aid, and a lubricant, wherein the water-soluble polymer carrier is Soluplus, the filler is anhydrous calcium hydrogen phosphate, the flow aid is colloidal silica, and the lubricant is sodium stearate fumarate.

[0024] In a preferred embodiment, the pharmaceutical composition contains, by weight, 5-15 parts of veneclade, 10-60 parts of water-soluble polymer carrier, 10-60 parts of filler, 0.1-5 parts of flow aid, and 0.1-3 parts of lubricant, and optionally 0-20 parts of solubilizer.

[0025] In a preferred embodiment, the content of veneclade in the pharmaceutical composition is 9-13 parts by weight.

[0026] In a preferred embodiment, the content of the water-soluble polymer carrier in the pharmaceutical composition is 20-55 parts by weight, preferably 25-53 parts.

[0027] In a preferred embodiment, the filler content in the pharmaceutical composition is 20-55 parts by weight, preferably 24-53 parts.

[0028] In a preferred embodiment, the content of the glidant in the pharmaceutical composition is 0.5-3 parts by weight, preferably 1-2 parts.

[0029] In a preferred embodiment, the lubricant content in the pharmaceutical composition is 0.5-1 parts by weight.

[0030] In a preferred embodiment, the content of solubilizer in the pharmaceutical composition is 0-15 parts by weight, preferably 0-12 parts.

[0031] In a preferred embodiment, the pharmaceutical composition contains, by weight, 9-13 parts of veneclade, 25-53 parts of water-soluble polymer carrier, 24-53 parts of filler, 1-2 parts of flow aid, and 0.5-1 parts of lubricant, and optionally 0-12 parts of solubilizer.

[0032] In a preferred embodiment, the pharmaceutical composition contains, by weight, 9-10 parts of veneclade, 50-53 parts of copovidone, 28-32 parts of anhydrous dicalcium phosphate, 1-2 parts of colloidal silica, 0.5-1 parts of sodium stearate fumarate, and 5-6 parts of poloxamer.

[0033] In a preferred embodiment, the pharmaceutical composition contains, by weight, 9-13 parts of Veneclare, 45-50 parts of anhydrous dicalcium phosphate, 1-2 parts of colloidal silica, 0.5-1 parts of sodium stearate fumarate, and 35-40 parts of Soluolus.

[0034] A second aspect of the present invention provides a method for preparing a veneclade pharmaceutical composition as described in the first aspect of the present invention, comprising the following steps: S1. Prepare a Veinecla solid dispersion and pulverize it; S2. Add filler, flow aid and optional solubilizer and mix; S3. Add lubricant and mix thoroughly to prepare raw flakes; S4. Coating.

[0035] In a preferred embodiment, the preparation method S1 includes the following steps: S1a. Mix Veneclare and water-soluble polymer carrier to obtain a mixture; S1b. The mixture is extruded using a hot melt extruder to obtain the extrudate; S1c. Crushed.

[0036] In a preferred embodiment, the hot melt extrusion temperature in step S1b is 130℃-170℃, the screw speed is 100-500rpm, and the feed speed is 10-50rpm.

[0037] In a preferred embodiment, the crushing speed in step S1c is 7000-15000 rpm, and the feeding speed is 30-100 rpm.

[0038] In a preferred embodiment, the D of the pulverized solid dispersion in step S1 90 It ranges from 100 to 500 μm.

[0039] In a preferred embodiment, the lubricant in step S3 is passed through a 40-mesh sieve before total mixing.

[0040] In a preferred embodiment, the hardness of the raw sheet in step S3 is 120-360N.

[0041] In a preferred embodiment, the weight gain of the uncoated sheet is 4% after coating in step S4.

[0042] A third aspect of the present invention provides the use of a Veneclare pharmaceutical composition as described in the first aspect of the present invention or a Veneclare pharmaceutical composition prepared by the preparation method as described in the second aspect of the present invention in the preparation of a medicament for treating diseases related to Bcl-2 and / or Bcl-2.

[0043] In another preferred embodiment, the diseases associated with Bcl-2 and / or Bcl-2 are selected from the group consisting of: chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, acute myeloid leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, or multiple myeloma.

[0044] It should be understood that, within the scope of this invention, the above-described technical features of this invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. Attached Figure Description

[0045] Figure 1 Flowchart of the manufacturing process for Venecra tablets. Detailed Implementation

[0046] Through extensive and in-depth research, and through numerous screenings and tests, the inventors have developed a veneclade pharmaceutical composition comprising a solid dispersion and excipients. The solid dispersion comprises veneclade and a water-soluble polymer carrier; the excipients comprise fillers, flow aids, and lubricants, and optionally include solubilizers. The related substances in the pharmaceutical composition of this invention are significantly lower than those in the reference formulation, the dissolution profile fits the reference formulation, and the stability meets quality standards. The materials used in tablet preparation are all solid powders, resulting in smooth extrusion, reduced processing difficulty, and the equipment involved is all commonly used in solid dosage forms, enabling long-term, high-yield production, making it suitable for commercial production.

[0047] Beneficial effects of this invention: 1. The long-term stability of the pharmaceutical composition of the present invention is significantly improved compared with the reference formulation, the related substances (impurities) are significantly lower than those of the reference formulation (the impurity content is reduced by at least 2 to 4 times under harsh long-term testing conditions), the dissolution curve can be matched with the reference formulation, and the stability meets the quality standards.

[0048] 2. The original patent CN103282025B clearly teaches the advantages of adding a surfactant (such as Tween20) to a solid dispersion to improve dissolution compared to not adding a surfactant, in terms of process feasibility and stability of the solid dispersion. However, the solid dispersion of the present invention does not contain liquid surfactants, so not only is the dissolution performance of the formulation not adversely affected, but the preparation process is also simple, the processing difficulty is low, and it is suitable for commercial production.

[0049] the term Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0050] As used herein, the term “additional excipients” refers to all excipient components other than the solid dispersion described herein.

[0051] As used herein, the term “optionally” means that an event or condition described subsequently may or may not occur, including both the occurrence of the event or condition and its non-occurrence.

[0052] As used herein, the terms “containing” or “including (comprise)” can be open-ended, semi-closed, or closed. In other words, the terms also include “consistently made of” or “composed of”.

[0053] As used in this article, the terms "room temperature" or "normal temperature" refer to a temperature between 4 and 40 degrees Celsius. o C, preferably, 25±5 o C.

[0054] It should be noted that Soluplus in this invention can be used as a water-soluble polymer carrier or as a solubilizer. When Soluplus is selected as both a water-soluble polymer carrier and a solubilizer in the excipients, Soluplus as a water-soluble polymer carrier is a component inside the solid dispersion; Soluplus as a solubilizer is a component added to the pharmaceutical composition in addition to the solid dispersion.

[0055] The excipients used in the original formulation (reference formulation) of Venecra tablets (trade name: VENCLEXTA®) in this invention are: copovidone, colloidal silica, polysorbate 80, sodium stearate fumarate, and anhydrous calcium hydrogen phosphate.

[0056] The equipment and materials used in the experiment were sourced from the following sources: twin-screw extruder (Steer, Omicron 12P); Venexlax (Nanjing Changyou Pharmaceutical Technology Co., Ltd., batch number: VCL-708-230901); copovidone (BASF, batch number: 46186016K0); Soluplus (BASF, batch number: 96645175L0); anhydrous dicalcium phosphate (Shenzhen Youpuhui Pharmaceutical Co., Ltd., batch number: D4489A); colloidal silica (Evonik Specialty Chemicals, batch number: 234051320); sodium stearate fumarate (JRS, batch number: 3918); poloxamer (BASF, batch number: GNI09121B); sodium dodecyl sulfate (BASF, batch number: 0029657947); and Calecco film coating premix (Calecco Coating Technology Co., Ltd., batch number: THL105038).

[0057] Example 1 The formulation of the Venecra pharmaceutical composition is shown in Table 1, and the preparation method is as follows: Figure 1 As shown, the specific steps are as follows: 1) Mix the prescribed amount of API and water-soluble polymer carrier to obtain a mixture; 2) Extrude the mixture obtained in step 1 using a hot melt extruder to obtain the extrudate. The extrusion temperature is 130℃-170℃, the screw speed is 100-500rpm, and the feed speed is 10-50rpm. 3) After pulverizing the extrudate, add filler, solubilizer, and flow aid and mix. 4) Add the sieved lubricant and mix thoroughly to prepare raw sheets; 5) Coating with film coating materials.

[0058] Table 1, Example 1: Veneclare pharmaceutical composition prescription Example 2 The formulation of the Veneclare pharmaceutical composition is shown in Table 2, and the preparation method is the same as in Example 1.

[0059] Table 2, Example 2 Veneclare Pharmaceutical Composition Formulation Example 3 The formulation of the Veneclare pharmaceutical composition is shown in Table 3, and the preparation method is the same as in Example 1. The difference is that the solubilizer is sodium dodecyl sulfate.

[0060] Table 3, Example 3 Veneclare Pharmaceutical Composition Prescription Example 4 The formulation of the Venecra pharmaceutical composition is shown in Table 4, and the preparation method is the same as in Example 1. The difference is that the solubilizer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus).

[0061] Table 4, Example 4: Veneclare pharmaceutical composition prescription Example 5 The formulation of the Venecra pharmaceutical composition is shown in Table 5, and the preparation method is the same as in Example 1. The difference is that the solubilizer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus).

[0062] Table 5, Example 5 Veneclare Pharmaceutical Composition Formulation Example 6 The formulation of the Venecra pharmaceutical composition is shown in Table 6, and the preparation method is the same as in Example 1. The difference is that the water-soluble polymer carrier is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus), and the extrusion temperature in step 2 is 110℃-140℃.

[0063] Table 6, Example 6: Veneclare pharmaceutical composition prescription Example 7 The formulation of the Venecra pharmaceutical composition is shown in Table 7, and the preparation method is the same as in Example 1. The difference is that the water-soluble polymer carrier is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus), the solubilizer is sodium dodecyl sulfate, and the extrusion temperature in step 2 is 110℃-140℃.

[0064] Table 7, Example 7 Veneclare Pharmaceutical Composition Formulation Example 8 The formulation of the Venecra pharmaceutical composition is shown in Table 8, and the preparation method is the same as in Example 1. The difference is that the water-soluble polymer carrier is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus), the solubilizer is sodium dodecyl sulfate, and the extrusion temperature in step 2 is 110℃-140℃.

[0065] Table 8, Example 8: Veneclare pharmaceutical composition prescription Example 9 The formulation of the Venecra pharmaceutical composition is shown in Table 9, and the preparation method is the same as in Example 1. The difference is that the water-soluble polymer carrier is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus), and there is no solubilizer in the excipients.

[0066] Table 9 Example 9 Veneclare Pharmaceutical Composition Prescription Test Example 1: Dissolution Test Method Dissolution method: Following the FDA's dissolution method for veneclade tablets, the dissolution rate of the solid dispersion was determined using the reciprocating barrel method. A dissolution volume of 250 ml was used, with 0.05 mol / L sodium dihydrogen phosphate buffer (0.4% SDS-pH 6.8 ± 0.05) as the dissolution medium. The dissolution speed was 20 dpm, and the temperature was 37℃. 5 ml samples were taken at 30 min, 60 min, 90 min, 120 min, 180 min, and 240 min. The samples were filtered through a PVDF membrane, 3 ml was discarded, and 1 ml of the filtrate was placed in a liquid chromatography vial. The veneclade content was determined by HPLC, and the cumulative dissolution rate of the veneclade tablets was calculated.

[0067] Measurement method: Phenomenex Kinetex C8, 3.0 mm 100 mm, 2.6 µm column (or equivalent performance); injection volume 15 µL; flow rate 0.7 mL / min; detection wavelength 282 nm; column temperature 50 °C; mobile phase 0.025 mol / L ammonium acetate solution (pH 7.0) - acetonitrile - methanol = 30:35:35.

[0068] Table 10. Results of Dissolution Curve Determination f2 is the fit value, which indicates the degree of fit between the embodiments of the present invention and the reference formulation. The closer the value is to 100, the better. The dissolution curves show that when copovidone is used as the carrier, the formulation prepared with poloxamer as the excipient and solubilizer can fit well with the reference formulation (Example 2, f2=85). When Soluplus is used as the carrier, no solubilizer needs to be added to the excipient to achieve good fit with the reference formulation (Example 9, f2=91).

[0069] Test Example 2: Stability Determination Related substance detection method: Water symmetry C18, 250 4.6 mm, 5 µm; injection volume: 10 μL; flow rate: 1.0 ml / min; detection wavelength: 282 nm; column temperature: 40 °C; injector temperature: 15 °C; mobile phase A: 0.01 mol / L potassium dihydrogen phosphate solution (pH 3.0) - acetonitrile = 80:20, mobile phase B: acetonitrile, elution gradient as shown in Table 11.

[0070] Table 11: Elution gradient for related substances detection The tablets prepared in Examples 2 and 9 were packaged in HDPE bottles (with desiccant inside) and placed together with the reference formulation for stability testing at high temperature (60°C), high humidity (92.5%), and accelerated conditions (40°C, 75%RH).

[0071] Dissolution method: Refer to the dissolution method and determination method described in Test Example 1.

[0072] Related substance F: Related substance Z1: Related substance Z2: Table 12: Results of stability test of Venecra tablets The results are shown in Table 12. In Example 2, the product prepared under the formulation 9, after being stored under accelerated conditions for 6 months, had significantly lower levels of related substances and total impurities than the reference formulation; the dissolution rate showed no significant change compared to the 0-day test, indicating that the product properties were relatively stable.

[0073] The above description is merely an embodiment of the present invention and is not intended to limit the scope of the substantive technical content of the present invention. The substantive technical content of the present invention is broadly defined within the scope of the claims of the application. Any technical entity or method completed by others that is completely identical to or an equivalent modification of the claims of the application shall be deemed to be covered within the scope of the claims.

Claims

1. A Veneclare pharmaceutical composition, characterized in that, The pharmaceutical composition comprises a solid dispersion and excipients; the solid dispersion comprises Venecra and a water-soluble polymer carrier, and the excipients comprise fillers, flow aids and lubricants; and the solid dispersion does not contain surfactants.

2. The pharmaceutical composition according to claim 1, characterized in that, The added excipients also include a solubilizer.

3. The pharmaceutical composition according to claim 1, characterized in that, The water-soluble polymer carrier is selected from the following group: copovidone, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus), polyvinyl alcohol, or hydroxypropyl methylcellulose.

4. The pharmaceutical composition according to claim 1, characterized in that, The filler is selected from the group consisting of anhydrous dicalcium phosphate, microcrystalline cellulose, lactose, or starch.

5. The pharmaceutical composition according to claim 2, characterized in that, The solubilizer is selected from the group consisting of: poloxamer, sodium dodecyl sulfate, Soluplus, or vitamin E polyethylene glycol succinate.

6. The pharmaceutical composition according to claim 1, characterized in that, The flow aid is selected from the group consisting of colloidal silica or talc.

7. The pharmaceutical composition according to claim 1, characterized in that, The lubricant is selected from the group consisting of sodium stearate fumarate or magnesium stearate.

8. The pharmaceutical composition according to claim 2, characterized in that, The pharmaceutical composition contains, by weight, 5-15 parts of veneclade, 10-60 parts of water-soluble polymer carrier, 10-60 parts of filler, 0.1-5 parts of glidant, 0.1-3 parts of lubricant, and 0-20 parts of solubilizer.

9. A method for preparing the Veneclare pharmaceutical composition as described in claim 1, characterized in that, Includes the following steps: S1. Prepare a Veinecla solid dispersion and pulverize it; S2. Add filler and gliding agent and mix; S3. Add lubricant and mix thoroughly to prepare raw flakes; S4. Coating.

10. A method for preparing the Veneclare pharmaceutical composition as described in claim 2, characterized in that, Includes the following steps: S1. Prepare a Veinecla solid dispersion and pulverize it; S2. Add filler, gliding agent and solubilizer and mix; S3. Add lubricant and mix thoroughly to prepare raw flakes; S4. Coating.

11. Use of the pharmaceutical composition of any one of claims 1-8 in the preparation of a medicament for treating chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, acute myeloid leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, or multiple myeloma.

Citation Information

Patent Citations

  • Solid dispersions of melt extruded containing apoptosis inducers

    CN103282025B